Company Performance - Dun & Bradstreet reported quarterly earnings of $0.21 per share, exceeding the Zacks Consensus Estimate of $0.20 per share, and showing a year-over-year increase from $0.20 per share [1] - The company posted revenues of $579.8 million for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 0.02%, but up from $564.5 million a year ago [2] - Over the last four quarters, Dun & Bradstreet has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Movement and Outlook - Dun & Bradstreet shares have declined approximately 28% since the beginning of the year, compared to a decline of 5.3% for the S&P 500 [3] - The sustainability of the stock's price movement will largely depend on management's commentary during the earnings call [3] - The current consensus EPS estimate for the upcoming quarter is $0.24 on revenues of $595.09 million, and for the current fiscal year, it is $1.04 on revenues of $2.46 billion [7] Industry Context - The Business - Information Services industry, to which Dun & Bradstreet belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The current estimate revisions trend for Dun & Bradstreet is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]

Huntington Ingalls (HII) came out with quarterly earnings of $3.79 per share, beating the Zacks Consensus Estimate of $2.90 per share. This compares to earnings of $3.87 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 30.69%. A quarter ago, it was expected that this shipbuilder would post earnings of $3.28 per share when it actually produced earnings of $3.15, delivering a surprise of -3.96%.Over the last four quarters, the co ...

Wayfair (W) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.18 per share. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 155.56%. A quarter ago, it was expected that this online home goods retailer would post earnings of $0.02 per share when it actually produced a loss of $0.25, delivering a surprise of -1,350%.Over the last four quarters ...

Organon (OGN) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $1.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.61%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.86 per share when it actually produced earnings of $0.90, delivering a surprise of 4.65%.Over the last four quarters, the com ...

Core Insights - Biogen Inc. reported quarterly earnings of $3.02 per share, missing the Zacks Consensus Estimate of $3.26 per share, and down from $3.67 per share a year ago, representing an earnings surprise of -7.36% [1] - The company posted revenues of $2.43 billion for the quarter, exceeding the Zacks Consensus Estimate by 8.91%, and up from $2.29 billion year-over-year [2] - Biogen shares have declined approximately 20.8% since the beginning of the year, compared to a decline of -5.3% for the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $4.10 on revenues of $2.33 billion, and for the current fiscal year, it is $15.63 on revenues of $9.17 billion [7] - The estimate revisions trend for Biogen is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Biogen belongs, is currently in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Puma Biotech, is expected to report quarterly earnings of $0.02 per share, reflecting a year-over-year change of +140%, with revenues anticipated at $43.96 million, up 0.4% from the previous year [9][10]

Core Viewpoint - Iron Mountain (IRM) reported quarterly earnings of $1.17 per share, exceeding the Zacks Consensus Estimate of $1.16 per share, and showing significant growth from $0.43 per share a year ago, indicating a positive earnings surprise of 0.86% [1] Financial Performance - The company posted revenues of $1.59 billion for the quarter ended March 2025, which was below the Zacks Consensus Estimate by 0.40%, but an increase from $1.48 billion year-over-year [2] - Over the last four quarters, Iron Mountain has surpassed consensus EPS estimates only once, and it has topped consensus revenue estimates two times [2] Stock Performance - Iron Mountain shares have declined approximately 14.7% since the beginning of the year, contrasting with the S&P 500's decline of 5.3% [3] - The current Zacks Rank for Iron Mountain is 5 (Strong Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.20 on revenues of $1.67 billion, and for the current fiscal year, it is $4.91 on revenues of $6.74 billion [7] - The trend for estimate revisions ahead of the earnings release was unfavorable, which may impact future stock movements [6] Industry Context - The Business - Information Services industry, to which Iron Mountain belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Eli Lilly (LLY) came out with quarterly earnings of $3.34 per share, missing the Zacks Consensus Estimate of $3.52 per share. This compares to earnings of $2.58 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.11%. A quarter ago, it was expected that this drugmaker would post earnings of $5.03 per share when it actually produced earnings of $5.32, delivering a surprise of 5.77%.Over the last four quarters, the company has su ...

Teleflex (TFX) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.88 per share. This compares to earnings of $3.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.04%. A quarter ago, it was expected that this medical equipment maker would post earnings of $3.86 per share when it actually produced earnings of $3.89, delivering a surprise of 0.78%.Over the last four quarters, the co ...

Core Viewpoint - Smurfit Westrock reported quarterly earnings of $0.73 per share, exceeding the Zacks Consensus Estimate of $0.65 per share, and showing significant growth from $0.39 per share a year ago, indicating a positive earnings surprise of 12.31% [1][2] Financial Performance - The company posted revenues of $7.66 billion for the quarter ended March 2025, which was 2.47% below the Zacks Consensus Estimate, and a substantial increase from $4.73 billion in the same quarter last year [2] - Over the last four quarters, Smurfit Westrock has only surpassed consensus EPS estimates once, indicating challenges in meeting revenue expectations [2] Stock Performance - Smurfit Westrock shares have declined approximately 22% since the beginning of the year, contrasting with the S&P 500's decline of 5.3%, suggesting underperformance relative to the broader market [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $0.80 for the upcoming quarter and $2.97 for the current fiscal year, alongside projected revenues of $8.04 billion and $31.79 billion respectively [7] - The Zacks Rank for Smurfit Westrock is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Paper and Related Products industry, to which Smurfit Westrock belongs, is currently ranked in the top 19% of over 250 Zacks industries, suggesting a favorable industry outlook that could positively influence stock performance [8]

CVS Health (CVS) came out with quarterly earnings of $2.25 per share, beating the Zacks Consensus Estimate of $1.71 per share. This compares to earnings of $1.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 31.58%. A quarter ago, it was expected that this drugstore chain and pharmacy benefits manager would post earnings of $0.89 per share when it actually produced earnings of $1.19, delivering a surprise of 33.71%.Over the ...